Related Experiment Videos
Restricted frontomesial epileptogenic focus generating dyskinetic behavior and laughter
Serge Chassagnon1, Lorella Minotti, Stephane Kremer
1Service de Neurologie, Neuropsychologie et explorations fonctionnelles des épilepsies, hospices civils de Strasbourg, Strasbourg, France.
Epilepsia
|June 7, 2003
Summary
Gelastic seizures, characterized by laughter, were pinpointed to the supplementary motor area and cingulate cortex. This finding offers new insights into the brain regions responsible for laughter and associated motor symptoms.
Area of Science:
- Neuroscience
- Epileptology
- Functional Neurosurgery
Background:
- Gelastic seizures are often associated with laughter and can present with complex motor behaviors.
- The precise anatomical origins of gelastic seizures, particularly those involving laughter and dyskinesia, remain incompletely understood.
- Cerebral MRI is often normal in patients with gelastic seizures, necessitating advanced neurophysiological investigation.
Observation:
- Stereo-electro-encephalography (SEEG) was performed in a patient experiencing gelastic seizures with dyskinetic behavior and ictal laughter.
- The patient had no visible abnormalities on cerebral MRI.
- Seizure activity was localized to the anterior and ventral supplementary motor area (SMA) and the dorsal cingulate cortex.
Findings:
- The epileptogenic zone was precisely identified within the anterior/ventral SMA and adjacent dorsal cingulate cortex.
- Minimal seizure spread to neighboring cortical areas was observed.
- The patient achieved seizure freedom for 27 months post-stereotactic radiofrequency ablation of the identified focus.
Implications:
- Pericingulate premotor areas are implicated in the generation of the motor component of laughter during seizures.
- The co-occurrence of paroxysmal dyskinesias with laughter may indicate involvement of specific basal ganglia circuits.
- This study refines our understanding of the neuroanatomical basis of gelastic seizures and associated phenomena, guiding potential therapeutic targets.